Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 9.06B P/E - EPS this Y -114.00% Ern Qtrly Grth -
Income 4.74B Forward P/E -10.83 EPS next Y -65.80% 50D Avg Chg 15.00%
Sales 158.3M PEG - EPS past 5Y - 200D Avg Chg 45.00%
Dividend N/A Price/Book 7.75 EPS next 5Y - 52W High Chg -2.00%
Recommedations 1.70 Quick Ratio 27.41 Shares Outstanding 739.52M 52W Low Chg 311.00%
Insider Own 29.09% ROA -15.03% Shares Float 363.16M Beta 1.26
Inst Own 74.86% ROE 127.72% Shares Shorted/Prior 33.57M/40.90M Price 11.81
Gross Margin -230.59% Profit Margin 2,991.76% Avg. Volume 4,793,029 Target Price 17.06
Oper. Margin -402.44% Earnings Date Nov 11 Volume 1,997,846 Change -1.01%
About Roivant Sciences Ltd.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd. News
11/19/24 Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
11/12/24 Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
10/29/24 Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
10/28/24 Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
09/18/24 Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
09/10/24 Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
09/10/24 Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
09/09/24 Roivant Provides Update on Graves’ Disease Development Program
09/04/24 The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy
08/22/24 Shareholders In Roivant Sciences (NASDAQ:ROIV) Should Look Beyond Earnings For The Full Story
08/08/24 Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
07/25/24 Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
05/30/24 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
05/16/24 Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
05/05/24 Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
04/02/24 Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
03/26/24 Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
02/14/24 Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
02/13/24 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
02/10/24 Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares
ROIV Chatroom

User Image VipMemberOfficial Posted - 46 minutes from now

📈 Stock Performance for $ROIV over the Last Month: Opening Price: $11.60 Closing Price: $12.53 Highest Price: $12.57 Lowest Price: $11.05

User Image brs555 Posted - 10 hours ago

$ROIV move up must be because of the comments by the analyst interviewing $ABUS execs. Big block trade today as well.

User Image Jmac98 Posted - 10 hours ago

@RonIsWrong Wouldn’t touch any company affiliated with that pos Vivek…. Just saying. $ROIV $IMVT

User Image DocPharm Posted - 11 hours ago

$ROIV keep on churnin - their buyback should be done soon

User Image 5htc2 Posted - 13 hours ago

$ROIV Could this finally be the moment we break above 12 for good? The sky above is blue.

User Image DocPharm Posted - 14 hours ago

$ROIV when it starts to run…remember there’s always (98.1% of the time) a corrective motion back to the handle… Good chance to flip and acquire more if you dare ;)

User Image Yerski24 Posted - 15 hours ago

$ROIV almost a teenager 😱

User Image SpaceCityKid Posted - 15 hours ago

$ROIV Starting to make it's move??

User Image RonIsWrong Posted - 15 hours ago

$ROIV big one (hey, it's over $12!)

User Image Myles_McBride Posted - 16 hours ago

🚨 MYNZ Petra Brand Ambassador says to keep an eye on "BIG NEWS from the NFL." This is going to run parabolic soon, right after the healthcare giant Thermo Fisher ($210B mkt cap) partnered with Mainz to develop and launch together ColoAlert in US 🚀 Buy the dip now, the train is leaving very soon. $EXEL $ITCI $ROIV

User Image SirSloth Posted - 16 hours ago

$ROIV Hi!

User Image SpaceCityKid Posted - 1 day ago

$ROIV In fact, it looks like it may be ready to emerge out of a 1+ year cup and handle. That could be really big. IMO, it has a lot to do with ABUS

User Image SpaceCityKid Posted - 1 day ago

$ROIV Were close now. Ready to b/o of falling channel.

User Image DocPharm Posted - 1 day ago

$ABUS Roivant buys another 100 mil and then runs the study themselves or with a BP, eventually selling it off, with or without Genevant I don’t see $Roiv letting go of this very easily This could be bigger than their TL1a sale

User Image Johnny_Wayne Posted - 2 days ago

$ROIV greatest 4 year consolidation I’ve seen on a chart. Like sideways tornado 🌪️

User Image DocPharm Posted - 2 days ago

$ROIV still loading this one ….flatter than the earth 😂😂

User Image Aubriella_Petersen Posted - 2 days ago

$ITCI $ROIV LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Christopher4ik Posted - 2 days ago

[$ITCI $ROIV] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image DocPharm Posted - 3 days ago

$ROIV $ABUS geometry

User Image Kocatka Posted - 3 days ago

@Jsa8214 @I_H8_SHORTS Exactly, should only factor market cap when evaluating biotech. I believe the highest MC in the past year was a slightly above 15 million and right now we are at 5M. Berubicin could exceed 1 billion in global sales per year if the data proves out. A $250-$500 million market cap would be on the low end of expectations with good data read out but that's where partnership or buyout negotiations come in and since we have $ROIV CCO on the board becoming a Vant may be an viable option.

User Image brs555 Posted - 3 days ago

@GABIRODZ01 @Nile1 I've been rotating some from here and $ROIV into $SGMO the last few months.

User Image DogshtTrading Posted - 4 days ago

$ROIV $BGC $COIN $TSLA https://medium.com/insiderfinance/trump-grift-stocks-destined-to-pop-during-his-term-rabbit-hole-edition-f756f5b99d3d

User Image uzkcyhn Posted - 4 days ago

$ROIV - I suppose people do not know this is Vivek's company? It makes no sense $TSLA is ripping and this is not moving

User Image Nosh Posted - 1 week ago

$ROIV Tempted but will wait it out around $10.50 area...not like it is doing anything for ages anyway...glty.

User Image KAInvestor Posted - 1 week ago

$ROIV $ABUS Vivek vs Kennedy LOL hope we will find some Dollars in this bullshit

User Image LakasTamad Posted - 1 week ago

$ROIV Pennant uptrend for long term play

User Image Capitulation_0 Posted - 1 week ago

$ROIV Vast majority of the public has no idea about Vivek connection. If Elon started this company, it would be trading at $100.

User Image AndyBah Posted - 1 week ago

$ROIV I stand by this.

User Image DogshtTrading Posted - 1 week ago

$ROIV who here thinks Vivek’s slush fund gets the crypto treatment and rockets soon?

User Image swingingtech Posted - 1 week ago

$ASAN $ROIV $PCG https://wallstreetwaves.com/highlighting-wednesdays-significant-options-activity-asan-roiv-pcg/

Analyst Ratings
Cantor Fitzgerald Overweight Sep 19, 24
HC Wainwright & Co. Buy Sep 19, 24
B of A Securities Neutral Sep 11, 24
HC Wainwright & Co. Buy Sep 11, 24
Cantor Fitzgerald Overweight Sep 9, 24
HC Wainwright & Co. Buy Aug 19, 24
Piper Sandler Overweight Jul 10, 24
Cantor Fitzgerald Overweight Jun 18, 24
HC Wainwright & Co. Buy May 31, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Venker Eric Chief Operating Offi.. Chief Operating Officer Oct 02 Sell 10.39 1,200,000 12,468,000 595,397 10/04/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Oct 02 Option 3.85 1,200,000 4,620,000 748,424 10/04/23
MANCHESTER KEITH S Director Director Sep 28 Sell 11.55 6,896,144 79,650,463 5,023,787 10/02/23
SVF Investments (UK) Ltd Director Director Sep 28 Sell 12.60 10,000,000 126,000,000 73,031,667 10/02/23
Gold Daniel Allen Director Director Sep 28 Sell 11.55 10,000,000 115,500,000 5,023,787 10/02/23
QVT Financial LP Director Director Sep 28 Sell 11.55 10,000,000 115,500,000 5,023,787 10/02/23
Venker Eric President & COO President & COO Sep 27 Sell 13.02 500,000 6,510,000 595,397 09/29/23
Venker Eric President & COO President & COO Sep 27 Option 3.85 500,000 1,925,000 1,095,397 09/29/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 08 Sell 12.19 106,430 1,297,382 611,813 09/12/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 08 Option 3.85 106,430 409,756 718,243 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 08 Sell 12.18 99,350 1,210,083 197,950 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 08 Option 6.48 99,350 643,788 297,300 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 05 Sell 12 1,724 20,688 197,950 09/07/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 05 Option 6.48 1,724 11,172 199,674 09/07/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 04 Sell 11.89 93,964 1,117,232 611,813 09/06/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 04 Option 3.85 93,964 361,761 617,739 09/06/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 14 Sell 11.89 59,811 711,153 627,918 08/16/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 14 Option 3.85 59,811 230,272 687,729 08/16/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 03 Sell 11.93 44,629 532,424 627,918 08/07/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 03 Option 3.85 44,629 171,822 672,547 08/07/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Aug 01 Sell 12 4,017 48,204 199,328 08/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Aug 01 Option 6.48 4,017 26,030 203,009 08/03/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 31 Sell 11.9 195,166 2,322,475 627,918 08/02/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 31 Option 3.85 195,166 751,389 644,315 08/02/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 25 Option 3.85 125,534 483,306 651,540 07/27/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 25 Sell 10.92 125,534 1,370,831 627,918 07/27/23
Venker Eric President & COO President & COO Jul 20 Sell 11.12 374,466 4,164,062 644,215 07/24/23
Venker Eric President & COO President & COO Jul 20 Option 3.85 374,466 1,441,694 677,296 07/24/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jul 14 Sell 12 635 7,620 82,128 07/18/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jul 14 Option 6.48 635 4,115 82,228 07/18/23
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jun 22 Sell 9.9 13,000,000 128,700,000 12,884,307 06/26/23
VIKING GLOBAL PERFORMANCE LLC 10% Owner 10% Owner Jun 22 Sell 9.9 13,000,000 128,700,000 12,884,307 06/26/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jun 09 Sell 9.93 43,893 435,857 198,582 06/13/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jun 09 Option 5.12 43,893 224,732 242,475 06/13/23
Venker Eric President & COO President & COO Jun 07 Sell 9.88 299,585 2,959,900 660,097 06/09/23
Venker Eric President & COO President & COO Jun 07 Option 3.85 299,585 1,153,402 959,481 06/09/23
Venker Eric President & COO President & COO May 23 Option 3.85 415 1,598 676,183 05/25/23
Venker Eric President & COO President & COO May 23 Sell 9.85 415 4,088 675,768 05/25/23
Venker Eric President & COO President & COO May 09 Sell 9.23 238,724 2,203,423 675,768 05/11/23
Venker Eric President & COO President & COO May 09 Option 3.85 238,724 919,087 914,492 05/11/23
Venker Eric President & COO President & COO May 04 Sell 8.62 150,044 1,293,379 675,768 05/08/23
Venker Eric President & COO President & COO May 04 Option 3.85 150,044 577,669 736,974 05/08/23
Venker Eric President & COO President & COO May 01 Sell 8.43 288,989 2,436,177 675,768 05/03/23
Venker Eric President & COO President & COO May 01 Option 3.85 288,989 1,112,608 794,528 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer May 01 Sell 8.5 77,736 660,756 200,139 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer May 01 Option 3.85 77,736 299,284 215,656 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Apr 26 Sell 8.55 230,788 1,973,237 200,139 04/28/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Apr 26 Option 3.9 230,788 900,073 272,128 04/28/23
Venker Eric President & COO President & COO Apr 26 Sell 8.55 222,243 1,900,178 675,768 04/28/23
Venker Eric President & COO President & COO Apr 26 Option 3.85 222,243 855,636 751,591 04/28/23